Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
2.
Eur J Clin Microbiol Infect Dis ; 36(9): 1577-1585, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28378243

RESUMEN

During prosthetic joint infection (PJI), optimal surgical management with exchange of the device is sometimes impossible, especially in the elderly population. Thus, prolonged suppressive antibiotic therapy (PSAT) is the only option to prevent acute sepsis, but little is known about this strategy. We aimed to describe the characteristics, outcome and tolerance of PSAT in elderly patients with PJI. We performed a national cross-sectional cohort study of patients >75 years old and treated with PSAT for PJI. We evaluated the occurrence of events, which were defined as: (i) local or systemic progression of the infection (failure), (ii) death and (iii) discontinuation or switch of PSAT. A total of 136 patients were included, with a median age of 83 years [interquartile range (IQR) 81-88]. The predominant pathogen involved was Staphylococcus (62.1%) (Staphylococcus aureus in 41.7%). A single antimicrobial drug was prescribed in 96 cases (70.6%). There were 46 (33.8%) patients with an event: 25 (18%) with an adverse drug reaction leading to definitive discontinuation or switch of PSAT, 8 (5.9%) with progression of sepsis and 13 died (9.6%). Among patients under follow-up, the survival rate without an event at 2 years was 61% [95% confidence interval (CI): 51;74]. In the multivariate Cox analysis, patients with higher World Health Organization (WHO) score had an increased risk of an event [hazard ratio (HR) = 1.5, p = 0.014], whereas patients treated with beta-lactams are associated with less risk of events occurring (HR = 0.5, p = 0.048). In our cohort, PSAT could be an effective and safe option for PJI in the elderly.


Asunto(s)
Antibacterianos/uso terapéutico , Artritis Infecciosa/tratamiento farmacológico , Artritis Infecciosa/epidemiología , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Infecciones Relacionadas con Prótesis/epidemiología , Factores de Edad , Anciano de 80 o más Años , Artritis Infecciosa/microbiología , Artritis Infecciosa/mortalidad , Femenino , Humanos , Masculino , Infecciones Relacionadas con Prótesis/microbiología , Infecciones Relacionadas con Prótesis/mortalidad , Factores de Tiempo , Resultado del Tratamiento
4.
Med Mal Infect ; 46(7): 355-359, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27238366

RESUMEN

OBJECTIVE: We aimed to assess medical practices of French infectious disease specialists or any other relevant physicians related to the management of non-necrotizing cellulitis (NNC). METHODS: We sent an online questionnaire to members of the French Infectious Diseases Society (SPILF) mailing list in September 2015. RESULTS: A total of 108 specialists took part in the survey and 10% (11/107) declared to always admit NNC patients to hospital. As for the others, 18% declared to admit patients in more than 80% of cases, 49% in 50-80% of cases, 26% in 20-50% of cases, and 7% in less than 20% of cases. The most frequent criteria for hospital admission were severe sepsis/septic shock (99%), poor social conditions (99%), rapid extension of skin lesions (93%), high level of pain (86%), and failure of first-line antibiotic therapy (84%). Participants mentioned similar criteria for reasons to initiate the intravenous (IV) antibiotic therapy. Fifty-three percent of respondents declared initiating antibiotic therapy using the IV route in more than 80% of cases. Physicians declared that the usual antibiotic therapy duration were <7 days (6%), 8-10 days (57%), 11-14 days (34%), and >15 days (3%). CONCLUSION: Criteria for hospital admission and use of the IV route for antibiotic therapy as well as optimal treatment duration in patients presenting with NNC need to be detailed in guidelines and evaluated in prospective studies.


Asunto(s)
Antibacterianos/uso terapéutico , Celulitis (Flemón)/tratamiento farmacológico , Administración Oral , Atención Ambulatoria , Antibacterianos/administración & dosificación , Celulitis (Flemón)/complicaciones , Comorbilidad , Manejo de la Enfermedad , Progresión de la Enfermedad , Esquema de Medicación , Francia , Encuestas de Atención de la Salud , Hospitalización , Humanos , Hiperalgesia/etiología , Infusiones Intravenosas , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina/estadística & datos numéricos , Sepsis/tratamiento farmacológico , Sepsis/etiología
6.
Euro Surveill ; 18(24)2013 Jun 13.
Artículo en Inglés | MEDLINE | ID: mdl-23787161

RESUMEN

In May 2013, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection was diagnosed in an adult male in France with severe respiratory illness, who had travelled to the United Arab Emirates before symptom onset. Contact tracing identified a secondary case in a patient hospitalised in the same hospital room. No other cases of MERS-CoV infection were identified among the index case's 123 contacts, nor among 39 contacts of the secondary case, during the 10-day follow-up period.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Infecciones del Sistema Respiratorio/epidemiología , Viaje , Trazado de Contacto , Coronavirus/aislamiento & purificación , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/transmisión , Transmisión de Enfermedad Infecciosa/prevención & control , Resultado Fatal , Francia , Humanos , Masculino , Persona de Mediana Edad , Infecciones del Sistema Respiratorio/prevención & control , Infecciones del Sistema Respiratorio/transmisión , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Emiratos Árabes Unidos
7.
Med Mal Infect ; 42(10): 488-94, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23041372

RESUMEN

OBJECTIVE: The authors had for aim to describe the epidemiological and clinical characteristics, and the treatment of patients presenting with skin and soft tissue infections due to Panton-Valentine leukocidin (PVL) producing Staphylococcus aureus in the Nord-Pas-de-Calais (NPDC) region, North of France. METHODS: We included patients presenting with PVL producing S. aureus infection from seven hospitals in the NPDC region, between February 2004 and April 2008. We retrospectively collected patient data using a standardized questionnaire. The features of patients presenting with skin and soft tissue were then analyzed. RESULTS: PVL producing S. aureus was isolated from 64 patients. Fifty-four patients presented with skin and soft tissue infections. The mean age of patients was 23.8 years (63% male patients). The mean number of persons living with the infected patient was 4.5 (vs. 2.5 in NPDC). The lesions were abscesses with inflammatory signs in 64.8% of the cases (20% were necrotic). Among the patients, 70.3% carried a methicillin resistant strain. Antibiotics per os were used for 83.3% of patients; the first-line antibiotics were considered inadequate in 53.3% of the cases. Among the patients, 83.3% underwent surgery. Fourteen out of 38 patients with available data had been exposed to antibiotic therapy during the three months before hospital management. CONCLUSION: Recent exposure to antibiotics and living with a high number of persons are reasons to suspect a PVL producing S. aureus infection in patients with skin abscess.


Asunto(s)
Toxinas Bacterianas/biosíntesis , Exotoxinas/biosíntesis , Leucocidinas/biosíntesis , Infecciones de los Tejidos Blandos/microbiología , Infecciones Estafilocócicas/microbiología , Infecciones Cutáneas Estafilocócicas/microbiología , Staphylococcus aureus/metabolismo , Adolescente , Niño , Femenino , Humanos , Lactante , Masculino , Estudios Retrospectivos , Infecciones de los Tejidos Blandos/epidemiología , Infecciones Estafilocócicas/epidemiología , Infecciones Cutáneas Estafilocócicas/epidemiología , Adulto Joven
8.
Infection ; 39(5): 473-6, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21830134

RESUMEN

OBJECTIVES: To evaluate the role of Staphylococcus simulans in bone and joint infections (BJI) and determine their main characteristics. METHODS: A search of the database of the microbiology laboratories of Lille hospital and Tourcoing hospital was performed. Only results from blood, bone, and orthopedic device cultures were taken into account for hospitalized patients between January 2004 and January 2009. We considered cases in which S. simulans was the only bacteria isolated in all of the patients' biological samples with clinical and laboratory signs of infection. For patients with complete medical records, we recorded the clinical and epidemiological data. RESULTS: Six cases of BJI due to S. simulans were recorded, with five cases related to orthopedic devices infections. Three patients lived in rural areas. In four out of six patients, S. simulans was isolated in intraoperative biopsy material. In one patient, S. simulans grew in synovial fluid and in another in blood cultures only. The latter patient had a spondylodiscitis, and chronic foot ulcers due to gout disease were suspected to be the origin of the infection. All patients were healed after a mean follow up of 9 ± 3 months. Orthopedic devices were removed in four of the five patients concerned. The combination of rifampicin plus levofloxacin was used in four patients. CONCLUSION: The present data suggest that, even though S. simulans remains rarely observed in clinical pathology, its role in osteoarticular infections, especially in the case of infected orthopedic devices, is not exceptional. As for the antibiotic treatment, the combination of rifampicin and levofloxacin seems to be an effective strategy according to our clinical results.


Asunto(s)
Antibacterianos/uso terapéutico , Dispositivos de Fijación Ortopédica/efectos adversos , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus/aislamiento & purificación , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Francia , Humanos , Dispositivos de Fijación Ortopédica/microbiología , Infecciones Relacionadas con Prótesis/microbiología , Infecciones Estafilocócicas/microbiología , Staphylococcus/efectos de los fármacos , Resultado del Tratamiento
10.
Med Mal Infect ; 38(3): 146-52, 2008 Mar.
Artículo en Francés | MEDLINE | ID: mdl-18191514

RESUMEN

OBJECTIVE: The authors aimed to evaluate the in vitro activity of ertapenem against bacterial strains isolated from diabetic foot infections (DFI). METHODOLOGY: All diabetic patients hospitalized for a first episode of DFI (stages 2 to 4, according to the International Working Group of Diabetic Foot Classification) were selected in the Nîmes University hospital between January 2005 to December 2005. MICs were determined using both E-test strips and dilution methods on bacterial strains isolated from foot samples. RESULTS: Two hundred and fifty-two bacteria (154 Gram-positive cocci including 94 Staphylococcus aureus, 80 Gram-negative bacilli with 56 Enterobacteriaceae, and 18 anaerobes) were studied. Ertapenem was active against all Streptococcus spp., Enterobacteriaceae, anaerobes, and also against 89.8% of methicillin-susceptible S. aureus isolates. However, this antibiotic was active only against 31.5% of Staphylococcus epidermidis, 21.8% of Enterococcus faecalis, and 15.8% of Pseudomonas aeruginosa. CONCLUSION: Our results indicate that ertapenem may be a useful agent to treat patients suffering from DFI after bacterial identification.


Asunto(s)
Antibacterianos/farmacología , Pie Diabético/complicaciones , Bacterias Gramnegativas/efectos de los fármacos , Infecciones por Bacterias Gramnegativas/microbiología , Bacterias Grampositivas/efectos de los fármacos , Infecciones por Bacterias Grampositivas/microbiología , beta-Lactamas/farmacología , Pie Diabético/microbiología , Evaluación Preclínica de Medicamentos , Ertapenem , Bacterias Gramnegativas/aislamiento & purificación , Infecciones por Bacterias Gramnegativas/etiología , Bacterias Grampositivas/aislamiento & purificación , Infecciones por Bacterias Grampositivas/etiología , Humanos , Pacientes Internos , Pruebas de Sensibilidad Microbiana , Especificidad de la Especie , Infecciones Estafilocócicas/microbiología , Resistencia betalactámica
11.
Ann Fr Anesth Reanim ; 25(5): 525-7, 2006 May.
Artículo en Francés | MEDLINE | ID: mdl-16503109

RESUMEN

A 39-year-old man was hospitalized after divalproate self-poisoning. He presented coma requiring tracheal intubation and mechanical ventilation at 11 hours and central diabetes insipidus. Serum valproic acid concentration was 590 mg/l at 30 hours. Progressive improvement occurred after hydratation and administration of vasopressin.


Asunto(s)
Diabetes Insípida/inducido químicamente , Ácido Valproico/envenenamiento , Adulto , Trastorno Bipolar/complicaciones , Trastorno Bipolar/tratamiento farmacológico , Coma/inducido químicamente , Diabetes Insípida/tratamiento farmacológico , Diabetes Insípida/terapia , Fluidoterapia , Humanos , Intubación Intratraqueal , Masculino , Intoxicación/sangre , Intoxicación/terapia , Poliuria/etiología , Respiración Artificial , Intento de Suicidio , Vasopresinas/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...